Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Antoni Torres (Barcelona, Spain). Should steroids be used in community-acquired pneumonia? Pro argument. International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate

Member's Comments

No comment yet.

Related content which might interest you: Should macrolides be given to all patients with community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Should steroids be used in community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Should macrolides be given to all patients with community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future! Source: Eur Respir J 2008; 31: 1150-1152 Year: 2008 What is pneumonia? Source: Breathe, 17 (3) 210087; 10.1183/20734735.0087-2021 Year: 2021 Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Corticosteroids for community-acquired pneumonia: a critical view of the evidence Source: Eur Respir J 2016; 48: 984-986 Year: 2016 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Mixed community-acquired pneumonia in hospitalised patients Source: Eur Respir J 2006; 27: 795-800 Year: 2006 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Update on community-acquired pneumonia Source: International Congress 2017 – ME5 Update on community-acquired pneumonia Year: 2017 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 COPD: what is the frequency and impact of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008 Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007 Epidemiology of community-acquired pneumonia and nosocomial pneumonia Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006